Silibinin inhibits prostate cancer cells- and RANKL-induced osteoclastogenesis by targeting NFATc1, NF-κB, and AP-1 activation in RAW264.7 cells
Published 2012 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Silibinin inhibits prostate cancer cells- and RANKL-induced osteoclastogenesis by targeting NFATc1, NF-κB, and AP-1 activation in RAW264.7 cells
Authors
Keywords
-
Journal
MOLECULAR CARCINOGENESIS
Volume 53, Issue 3, Pages 169-180
Publisher
Wiley
Online
2012-11-01
DOI
10.1002/mc.21959
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Cancer statistics, 2012
- (2012) Rebecca Siegel et al. CA-A CANCER JOURNAL FOR CLINICIANS
- TNFα inhibits the development of osteoclasts through osteoblast-derived GM-CSF
- (2011) Elvis Atanga et al. BONE
- Role of E-cadherin in Antimigratory and Antiinvasive Efficacy of Silibinin in Prostate Cancer Cells
- (2011) G. Deep et al. Cancer Prevention Research
- Denosumab for the management of bone disease in patients with solid tumors
- (2011) Jean-Jacques Body Expert Review of Anticancer Therapy
- Adiponectin Inhibits Osteoclastogenesis and Bone Resorption via APPL1-mediated Suppression of Akt1
- (2011) Qisheng Tu et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Osteoblastogenesis and osteoprotection enhanced by flavonolignan silibinin in osteoblasts and osteoclasts
- (2011) Jung-Lye Kim et al. JOURNAL OF CELLULAR BIOCHEMISTRY
- Purification and identification of lactoperoxidase in milk basic proteins as an inhibitor of osteoclastogenesis
- (2011) Y. Morita et al. JOURNAL OF DAIRY SCIENCE
- Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study
- (2011) Karim Fizazi et al. LANCET
- Denosumab and bone-metastasis-free survival in men with castration-resistant prostate cancer: results of a phase 3, randomised, placebo-controlled trial
- (2011) Matthew R Smith et al. LANCET
- Positive regulators of osteoclastogenesis and bone resorption in rheumatoid arthritis
- (2011) Tobias Braun et al. ARTHRITIS RESEARCH & THERAPY
- RANKL-independent human osteoclast formation with APRIL, BAFF, NGF, IGF I and IGF II
- (2010) F. Hemingway et al. BONE
- Antimetastatic efficacy of silibinin: molecular mechanisms and therapeutic potential against cancer
- (2010) Gagan Deep et al. CANCER AND METASTASIS REVIEWS
- The role of RANKL and MMP-9 in the bone resorption caused by ameloblastoma
- (2010) Yong Qian et al. JOURNAL OF ORAL PATHOLOGY & MEDICINE
- Optimizing Clinical Benefits of Bisphosphonates in Cancer Patients with Bone Metastases
- (2010) M. Aapro et al. ONCOLOGIST
- GM-CSF and IL-4 induce dendritic cell differentiation and disrupt osteoclastogenesis through M-CSF receptor shedding by up-regulation of TNF- converting enzyme (TACE)
- (2009) M. Hiasa et al. BLOOD
- Growth Inhibition and Regression of Lung Tumors by Silibinin: Modulation of Angiogenesis by Macrophage-Associated Cytokines and Nuclear Factor- B and Signal Transducers and Activators of Transcription 3
- (2009) A. Tyagi et al. Cancer Prevention Research
- Silibinin Suppresses Growth of Human Prostate Carcinoma PC-3 Orthotopic Xenograft via Activation of Extracellular Signal-Regulated Kinase 1/2 and Inhibition of Signal Transducers and Activators of Transcription Signaling
- (2009) R. P. Singh et al. CLINICAL CANCER RESEARCH
- NFATc1: Functions in osteoclasts
- (2009) Qingxiao Zhao et al. INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY
- The Mechanism of Osteoclast Differentiation Induced by IL-1
- (2009) J. H. Kim et al. JOURNAL OF IMMUNOLOGY
- The critical role of the bone microenvironment in cancer metastases
- (2009) Sandra Casimiro et al. MOLECULAR AND CELLULAR ENDOCRINOLOGY
- Silibinin suppresses growth and induces apoptotic death of human colorectal carcinoma LoVo cells in culture and tumor xenograft
- (2009) M. Kaur et al. MOLECULAR CANCER THERAPEUTICS
- Silibinin inhibits osteoclast differentiation mediated by TNF family members
- (2009) Jung Ha Kim et al. MOLECULES AND CELLS
- Tumor–stroma co-evolution in prostate cancer progression and metastasis
- (2009) Sajni Josson et al. SEMINARS IN CELL & DEVELOPMENTAL BIOLOGY
- Molecular mechanisms of metastasis in prostate cancer
- (2008) Noel W. Clarke et al. ASIAN JOURNAL OF ANDROLOGY
- Mechanisms of bone metastasis in prostate cancer: clinical implications
- (2008) Pavlos Msaouel et al. BEST PRACTICE & RESEARCH CLINICAL ENDOCRINOLOGY & METABOLISM
- Targeting the receptor activator of nuclear factor-κB (RANK) ligand in prostate cancer bone metastases
- (2008) Fred Saad et al. BJU INTERNATIONAL
- Osteotropic cancers: From primary tumor to bone
- (2008) Jeroen T. Buijs et al. CANCER LETTERS
- Stage-Specific Inhibitory Effects and Associated Mechanisms of Silibinin on Tumor Progression and Metastasis in Transgenic Adenocarcinoma of the Mouse Prostate Model
- (2008) K. Raina et al. CANCER RESEARCH
- Silibinin Inhibits Established Prostate Tumor Growth, Progression, Invasion, and Metastasis and Suppresses Tumor Angiogenesis and Epithelial-Mesenchymal Transition in Transgenic Adenocarcinoma of the Mouse Prostate Model Mice
- (2008) R. P. Singh et al. CLINICAL CANCER RESEARCH
- Isosilibinin inhibits advanced human prostate cancer growth in athymic nude mice: Comparison with silymarin and silibinin
- (2008) Gagan Deep et al. INTERNATIONAL JOURNAL OF CANCER
- Isosilybin B causes androgen receptor degradation in human prostate carcinoma cells via PI3K-Akt-Mdm2-mediated pathway
- (2008) G Deep et al. ONCOGENE
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started